--- title: "What is Wedbush's Forecast for Geron Q1 Earnings?" description: "Wedbush has released its Q1 2026 earnings estimates for Geron Corporation (NASDAQ: GERN), projecting an EPS of ($0.02). The consensus for the full year is ($0.25) per share. Geron reported a revenue o" type: "news" locale: "en" url: "https://longbridge.com/en/news/252339428.md" published_at: "2025-08-09T14:54:06.000Z" --- # What is Wedbush's Forecast for Geron Q1 Earnings? > Wedbush has released its Q1 2026 earnings estimates for Geron Corporation (NASDAQ: GERN), projecting an EPS of ($0.02). The consensus for the full year is ($0.25) per share. Geron reported a revenue of $49.04 million for the last quarter, exceeding expectations. The stock has received mixed ratings from analysts, with a consensus rating of "Moderate Buy" and a target price of $4.61. Geron focuses on therapeutics for hematologic malignancies, with its key product, imetelstat, in Phase 3 trials. - Geron Corporation: FDA Approval Fuels Stock Price Surge Geron Corporation (NASDAQ:GERN - Free Report) - Wedbush issued their Q1 2026 earnings per share (EPS) estimates for Geron in a research note issued to investors on Wednesday, August 6th. Wedbush analyst R. Driscoll expects that the biopharmaceutical company will earn ($0.02) per share for the quarter. The consensus estimate for Geron's current full-year earnings is ($0.25) per share. Wedbush also issued estimates for Geron's Q2 2026 earnings at $0.00 EPS, Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.04 EPS, FY2026 earnings at $0.04 EPS and FY2027 earnings at $0.37 EPS. Geron (NASDAQ:GERN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.01. The business had revenue of $49.04 million during the quarter, compared to analysts' expectations of $47.30 million. Geron had a negative return on equity of 30.79% and a negative net margin of 53.52%. The business's quarterly revenue was up 5455.6% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.10) earnings per share. - Geron Stock Doubles After Imetelstat Receives FDA Panel Approval GERN has been the subject of several other research reports. The Goldman Sachs Group initiated coverage on Geron in a research report on Thursday, July 10th. They set a "sell" rating and a $1.00 target price for the company. Scotiabank cut Geron from a "sector outperform" rating to a "sector perform" rating and cut their target price for the stock from $4.00 to $1.50 in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Geron has a consensus rating of "Moderate Buy" and a consensus price target of $4.61. **View Our Latest Stock Report on GERN** ## Geron Stock Performance GERN traded down $0.02 during midday trading on Friday, reaching $1.29. The company had a trading volume of 2,104,608 shares, compared to its average volume of 12,713,486. The company has a quick ratio of 6.97, a current ratio of 7.87 and a debt-to-equity ratio of 0.44. The business has a 50-day moving average of $1.39 and a two-hundred day moving average of $1.68. The company has a market cap of $818.44 million, a P/E ratio of -9.88 and a beta of 0.73. Geron has a 1 year low of $1.09 and a 1 year high of $4.84. ## Institutional Investors Weigh In On Geron Institutional investors have recently modified their holdings of the stock. Integrated Wealth Concepts LLC bought a new stake in shares of Geron in the 4th quarter valued at approximately $36,000. GF Fund Management CO. LTD. purchased a new stake in Geron in the fourth quarter worth $45,000. 111 Capital bought a new stake in shares of Geron during the fourth quarter worth $52,000. Fifth Lane Capital LP bought a new stake in shares of Geron during the fourth quarter worth $53,000. Finally, Harvest Investment Services LLC bought a new stake in shares of Geron during the fourth quarter worth $61,000. 73.71% of the stock is owned by institutional investors. ## About Geron (Get Free Report) Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. ## See Also - Five stocks we like better than Geron - What is the MACD Indicator and How to Use it in Your Trading - Why Axon's 16% Surge Signals a New Era in Public Safety Tech - High Dividend REITs: Are They an Ideal Way to Diversify? - DraftKings Posts Record Quarter, Eyes Profitability - Insider Selling Explained: Can it Inform Your Investing Choices? - Amazon Takes an Equity Stake in IonQ—Any Upside Potential? *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Geron Right Now? Before you consider Geron, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Geron wasn't on the list. While Geron currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [GERN.US - Geron](https://longbridge.com/en/quote/GERN.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 在较温和的近期指导、资本纪律和管线催化剂之间取得平衡：为什么杰龙公司值得被给予买入评级和 4 美元的目标价 | Geron 收到了 Needham 分析师 Gil Blum 的买入评级，他设定了 4.00 美元的目标价。尽管短期指引较为疲软，Blum 预计 Rytelo 将实现两位数增长，并将公司的成本管理视为战略上的积极因素。他相信 Geron 可 | [Link](https://longbridge.com/en/news/272348012.md) | | 杰龙公司延长与 Pharmakon 基金的 2.5 亿美元贷款便利条款 | 杰龙公司已修订与 Pharmakon Advisors 的贷款协议，延长了 2.5 亿美元高级担保定期贷款的条款。该贷款分为三个部分：1.25 亿美元将在 2024 年 11 月提供，7500 万美元可由杰龙选择使用，5000 万美元则取决 | [Link](https://longbridge.com/en/news/271640786.md) | | 一场由减肥 “神药” 引发的 “甜味危机”：糖价腰斩，连梦龙也卖不动了！ | GLP-1 类减肥药正通过改变饮食行为，重塑糖与蛋白质的需求结构，并迅速传导至期货与股票市场。纽约原糖期货跌破 14 美分，创 2020 年以来新低，较 2023 年末高点腰斩。全球最大冰淇淋公司梦龙在销量不及预期后股价大跌，引发对冰淇淋等 | [Link](https://longbridge.com/en/news/275766631.md) | | 爱克斯龙｜8-K：2025 财年 Q4 营收 54.12 亿美元不及预期 | | [Link](https://longbridge.com/en/news/275752391.md) | | 爱克斯龙将季度股息提高至每股 0.42 美元，将于 3 月 13 日支付给截至 3 月 2 日的登记股东 | 爱克斯龙将季度股息提高至每股 0.42 美元，支付日期为 3 月 13 日，记录日期为 3 月 2 日 | [Link](https://longbridge.com/en/news/275789362.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.